default author photo

Henry G. Grabowski

Duke University - Department of Economics

Professor

213 Social Sciences Building

Box 90097

Durham, NC 27708-0204

United States

  • Duke University - Department of Economics

    • Email
    • Tel: 919-660-1839
SCHOLARLY PAPERS

5

DOWNLOADS

1,941

TOTAL CITATIONS
Rank 48,563

SSRN RANKINGS

Top 48,563

in Total Papers Citations

18

Scholarly Papers (5)

Actions:
Email selected abstracts
1.

Longer Patents for Increased Generic Competition: The Waxman-Hatch Act after One Decade

Duke Economics Working Paper #95-11
Number of pages: 34 Posted: 26 Nov 1997
Henry G. Grabowski and John M. Vernon
Duke University - Department of Economics and Duke University - Department of Economics
Downloads 1,254 (41,034)
Citation 18

Abstract:

Loading...

2.

Entry and Competition in Generic Biologics

Managerial and Decision Economics, 2007
Number of pages: 39 Posted: 17 Jul 2007 Last Revised: 20 Sep 2014
Henry G. Grabowski, David B. Ridley and Kevin A. Schulman
Duke University - Department of Economics, Duke University - Fuqua School of Business and Duke University - Medical Center
Downloads 574 (118,447)

Abstract:

Loading...

generic, biologic, biological

3.

One Year after the Launch of the First U.S. Biosimilar Drug: Lessons for the Future?

Number of pages: 28 Posted: 09 Aug 2017
Henry G. Grabowski, Zoya Marriott, Penka Kovacheva and Andrew Elzinga
Duke University - Department of Economics, Cornerstone Research, Inc. - Boston Office, Cornerstone Research and Cornerstone Research
Downloads 113 (630,858)

Abstract:

Loading...

Biologic, Biosimilar, Drug Competition

4.

FDA Regulation of Biosimilars

FDA in the Twenty First Century: The Challenges of Regulating Drugs and New Technologies (Columbia University Press 2015)
Posted: 17 Sep 2015
Erika Lietzan and Henry G. Grabowski
University of Missouri School of Law and Duke University - Department of Economics

Abstract:

Loading...

biosimilars, generic drugs, BPCIA, Hatch-Waxman, price competition, innovation, cost savings, pharmaceuticals, biotechnology

5.

Do Faster FDA Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act

Journal of Law and Economics, Forthcoming, iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 17 Jun 2007
Henry G. Grabowski and Richard Wang
Duke University - Department of Economics and Temple University

Abstract:

Loading...